Posted by Michael Wonder on 27 Aug 2020
Cassiopea receives FDA approval for Winlevi (1% clascoterone cream), first in class topical acne treatment targeting the androgen receptor
27 August 2020 - Cassiopea today announced that the United States FDA approved Winlevi (1% clascoterone cream) for the treatment of acne in patients 12 years and older.
Notwithstanding acne being the most prevalent skin condition in the U.S. affecting up to 50 million Americans annually, the last FDA approval of an acne drug with a new mechanism of action occurred nearly 40 years ago.
